Project Grant HT94252510001

This Project Grant award from the National Institute on Aging (CFDA 93.866, Aging Research) provides $919,106 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at discovering and optimizing small molecules that can "correct" the function of the Alzheimer's disease risk factor APOE4 to be more similar to the lower-risk APOE3 variant. The key products and services to be delivered under this 5-year grant include developing a novel high-throughput...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...

This Cooperative Agreement awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) provides $810,698 in funding to Trustees of Boston University, doing business as Boston University Medical Campus, to conduct research on the impact of APOE genotype on Alzheimer's disease (AD) risk and underlying biological mechanisms. The project aims to: 1) Identify new APOE genotype-mediated AD associations using large genetic datasets, 2) Perform...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $373,600 to Weill Medical College of Cornell University to elucidate the cell-type specific neuroprotective mechanisms of the APOE3 Christchurch mutation in Alzheimer's disease. The key objectives of this 2.5-year project are to: 1) Determine the relationship between the interferon response in APOE3 Christchurch microglia and neuronal health/neurite outgrowth, and 2) Analyze the APOE3...

The National Institute on Aging awarded a $2,250,745 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic Jacksonville, doing business as Scott Lynch MD, to conduct research on the role of apolipoprotein E (APOE) in meningeal lymphatic function and its impact on Alzheimer's disease pathophysiology. The research aims to uncover the effects of APOE4 expression on meningeal lymphatic drainage and immune cell interactions, and how this may contribute to neuroinflammation and amyloid-β...

This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse...

This $564,530 Project Grant award, provided by the National Institute on Aging (CFDA 93.866 Aging Research program), will support research at Emory University to investigate the associative role of the Alzheimer's disease (AD) risk gene APOE4 and the menopause-related hormone follicle-stimulating hormone (FSH) in the initiation and progression of AD. The research aims to explore whether APOE4 facilitates AD pathology in women, particularly related to FSH-induced mechanisms, and examine if...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,248 to The Trustees of the University of Pennsylvania to investigate how disrupted autophagy contributes to inflammation and plaque formation in Alzheimer's disease. The research aims to: 1) Confirm that the APOE4 Alzheimer's risk variant disrupts mitochondria-endoplasmic...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $433,824 to the J. David Gladstone Institutes in San Francisco, CA to investigate how the Alzheimer's disease risk factor APOE4 disrupts the maturation and integration of adult-born dentate granule cells in the hippocampus. The research aims to elucidate the underlying transcriptomic changes and electrophysiological alterations that lead to hyperexcitability in these neurons, with the...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $341,000 to The Roskamp Institute, Inc. to examine the influence of different APOE genotypes on the GLP-1R-AMPK-ACC pathway in cerebrovascular cells and astrocytes, and to determine whether treatments that activate this pathway could regulate fatty acid oxidation in APOE4 carriers. This research aims to provide insights into developing approaches for targeting brain bioenergetic pathways to...